Diamond Therapeutics to present groundbreaking study at NIH event

Diamond Therapeutics to present groundbreaking study at NIH event
News provided by
Share this article
Share this article
Dr. Edward Sellers, head of Diamond's clinical advisory board, will speak about the benefits of low-dose psilocybin
TORONTO, May 27, 2021 /PRNewswire/ - Diamond Therapeutics Inc. ("
Diamond"), a leading psychedelic drug development company focused on sub-perceptual therapies for mental health, is pleased to announce that the head of its clinical advisory board, Dr. Edward Sellers, will be presenting at the NIH's Psilocybin Research Speaker Series on June 4, 2021.
Dr. Sellers, who is Professor Emeritus, Pharmacology and Toxicology, Medicine and Psychiatry at the University of Toronto, will be speaking from 12:30 to 1:00 EST.

Related Keywords

Toronto ,Ontario ,Canada , ,University Of Toronto ,Diamond Therapeutics Inc ,Psilocybin Research Speaker Series ,Evidence For Antidepressant Properties ,Psilocybin Research Speaker Series On ,Edward Sellers ,Diamond Therapeutics ,Research Speaker Series ,Professor Emeritus ,Psilocybin Enhance Motivation ,Poor Performing Rats ,Antidepressant Properties ,Low Doses ,Ketamine Enhance Motivation ,டொராண்டோ ,ஆஂடேரியொ ,கனடா ,பல்கலைக்கழகம் ஆஃப் டொராண்டோ ,வைரம் சிகிச்சை இன்க் ,எட்வர்ட் விற்பனையாளர்கள் ,வைரம் சிகிச்சை ,ப்ரொஃபெஸர் எமரிட்டஸ் ,குறைந்த அளவுகள் ,